Geistlich agrees takeover of US dentistry firm
Wolhusen/Schlieren/Franklin - Geistlich Pharma has acquired Lynch Biologics, a Tennessee-based regenerative dentistry company. With Lynch Biologics’ lead product for bone formation and wound healing, Geistlich has now moved to strengthen its portfolio of innovative products that are used around the world.
Geistlich Pharma is integrating Lynch Biologics in its existing subsidiary Geistlich Pharma North America based in Princeton in the US State of New Jersey. With this acquisition, the company from Wolhusen in the canton of Lucerne, which forms part of Geistlich Holding, headquartered in Schlieren in the canton of Zurich, is reinforcing its commitment to the US market. Moreover, it is strengthening its position as the global market leader in regenerative dentistry over the long term, further details of which can be found in a press release.
Lynch Biologics, based in the US state of Tennessee, has also been focusing on this sector since 2015. Its lead product GEM 21S, which is used worldwide, promotes and accelerates bone formation and wound healing. “Our two companies complement each other perfectly in terms of scientific focus and expertise in regeneration”, comments Dr. Ralf Halbach, CEO of Geistlich, in the press release. “We have long admired the pioneering spirit of Dr. Sam Lynch and welcome him and his team to our company”, he adds.
In order to support the regeneration of bones and tissue in the human body even more effectively, the two firms intend to intensify their activities in the areas of research, training, quality and safety. The North American firm Lynch Biologics is named after its CEO, Dr. Sam Lynch, who expressed his excitement about the merger, which will “bring new technologies to market for the benefit of patients”.
